FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236673766> ?p ?o ?g. }

• W4236673766 endingPage "TPS599" @default.
• W4236673766 startingPage "TPS599" @default.
• W4236673766 abstract "TPS599 Background: In-vitro and in-vivo evidence suggest that aspirin may have an anti-tumor effect. Multiple epidemiologic studies have reported improved breast cancer survival among regular aspirin users compared to non-users. Pooled data from randomized trials of aspirin for cardiovascular disease have also reported a decreased risk of metastatic cancer among aspirin users. However, the exact benefits and risks for breast cancer survivors need to be confirmed in a randomized controlled trial. Even if the clinical effect were modest, the global impact would be substantial since aspirin is inexpensive and widely available. Methods: The primary objective is to compare the effect of 300 mg daily aspirin versus placebo upon invasive disease-free survival (iDFS) in high risk HER2 negative breast cancer patients. Secondary objectives include effects on overall survival, cardiovascular disease, toxicity, and adherence. A biospecimen repository will be created for correlative analyses including tumor collection at baseline and blood and urine samples and questionnaires assessing lifestyle factors associated with inflammation (pain, sleep, stress, and depression) at baseline and 2 years. Study design: Subjects will be randomized (1:1) to aspirin 300 mg vs placebo daily for 5 years in a double-blinded fashion. Stratification factors include hormone receptor (HR) status (positive vs negative), body mass index ( < or ≥ 30 kg/m2), and stage (II vs III). Subjects will be followed every 6 six months while on study drug, then annually for 10 years. Accrual goal is 2936 patients to reach 381 iDFS events. We have 80% power to detect HR 0.75 assuming 5-year iDFS on placebo of 77%. Eligibility: Eligible subjects include patients aged 18-70 diagnosed with a primary invasive HER2 negative breast cancer. If HR positive, tumors need to be node positive and diagnosed within the past 10 years. If HR negative, tumors can be node positive or T2-4N0 within 18 months of diagnosis. Subjects who are currently anticoagulated or those with a prior history of GI bleeding, atrial fibrillation, or myocardial infarction are excluded. Subjects who regularly use aspirin (defined as ≥ 5 days per week) need to stop 30 days prior to enrollment. Updated accrual numbers will be given at the time of presentation. Clinical trial information: NCT02927249." @default.
• W4236673766 created "2022-05-12" @default.
• W4236673766 creator A5026770948 @default.
• W4236673766 creator A5039694693 @default.
• W4236673766 creator A5052268581 @default.
• W4236673766 creator A5065815573 @default.
• W4236673766 creator A5070245248 @default.
• W4236673766 creator A5073159738 @default.
• W4236673766 creator A5074015095 @default.
• W4236673766 creator A5081453283 @default.
• W4236673766 creator A5081509773 @default.
• W4236673766 creator A5089826071 @default.
• W4236673766 date "2019-05-20" @default.
• W4236673766 modified "2023-10-18" @default.
• W4236673766 title "ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer." @default.
• W4236673766 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.tps599" @default.
• W4236673766 hasPublicationYear "2019" @default.
• W4236673766 type Work @default.
• W4236673766 citedByCount "2" @default.
• W4236673766 countsByYear W42366737662021 @default.
• W4236673766 countsByYear W42366737662023 @default.
• W4236673766 crossrefType "journal-article" @default.
• W4236673766 hasAuthorship W4236673766A5026770948 @default.
• W4236673766 hasAuthorship W4236673766A5039694693 @default.
• W4236673766 hasAuthorship W4236673766A5052268581 @default.
• W4236673766 hasAuthorship W4236673766A5065815573 @default.
• W4236673766 hasAuthorship W4236673766A5070245248 @default.
• W4236673766 hasAuthorship W4236673766A5073159738 @default.
• W4236673766 hasAuthorship W4236673766A5074015095 @default.
• W4236673766 hasAuthorship W4236673766A5081453283 @default.
• W4236673766 hasAuthorship W4236673766A5081509773 @default.
• W4236673766 hasAuthorship W4236673766A5089826071 @default.
• W4236673766 hasConcept C121608353 @default.
• W4236673766 hasConcept C126322002 @default.
• W4236673766 hasConcept C141071460 @default.
• W4236673766 hasConcept C142724271 @default.
• W4236673766 hasConcept C143998085 @default.
• W4236673766 hasConcept C168563851 @default.
• W4236673766 hasConcept C204787440 @default.
• W4236673766 hasConcept C27081682 @default.
• W4236673766 hasConcept C2777628954 @default.
• W4236673766 hasConcept C530470458 @default.
• W4236673766 hasConcept C535046627 @default.
• W4236673766 hasConcept C71924100 @default.
• W4236673766 hasConceptScore W4236673766C121608353 @default.
• W4236673766 hasConceptScore W4236673766C126322002 @default.
• W4236673766 hasConceptScore W4236673766C141071460 @default.
• W4236673766 hasConceptScore W4236673766C142724271 @default.
• W4236673766 hasConceptScore W4236673766C143998085 @default.
• W4236673766 hasConceptScore W4236673766C168563851 @default.
• W4236673766 hasConceptScore W4236673766C204787440 @default.
• W4236673766 hasConceptScore W4236673766C27081682 @default.
• W4236673766 hasConceptScore W4236673766C2777628954 @default.
• W4236673766 hasConceptScore W4236673766C530470458 @default.
• W4236673766 hasConceptScore W4236673766C535046627 @default.
• W4236673766 hasConceptScore W4236673766C71924100 @default.
• W4236673766 hasIssue "15_suppl" @default.
• W4236673766 hasLocation W42366737661 @default.
• W4236673766 hasOpenAccess W4236673766 @default.
• W4236673766 hasPrimaryLocation W42366737661 @default.
• W4236673766 hasRelatedWork W2064286441 @default.
• W4236673766 hasRelatedWork W2066747782 @default.
• W4236673766 hasRelatedWork W2224319365 @default.
• W4236673766 hasRelatedWork W2332797319 @default.
• W4236673766 hasRelatedWork W2366434335 @default.
• W4236673766 hasRelatedWork W2542248393 @default.
• W4236673766 hasRelatedWork W3204761618 @default.
• W4236673766 hasRelatedWork W377899687 @default.
• W4236673766 hasRelatedWork W4214780584 @default.
• W4236673766 hasRelatedWork W4285097448 @default.
• W4236673766 hasVolume "37" @default.
• W4236673766 isParatext "false" @default.
• W4236673766 isRetracted "false" @default.
• W4236673766 workType "article" @default.